Managing Vesicant Risk During Oncology and SACT Infusions: The Role of Continuous IV Site Monitoring

August 2026

Intravenous administration of anticancer therapy, commonly referred to as Systemic Anti-Cancer Therapy (SACT) in the UK and oncology infusion therapy or intravenous chemotherapy in the US, remains a cornerstone of cancer care. These therapies carry a recognized risk of infiltration and extravasation where consequences can be significant and catastrophic, particularly when vesicant or highly irritant drugs are administered. Importantly, many cases begin with early leakage that may not be immediately detectable through routine IV site assessment.¹

Vesicant Chemotherapy and Tissue Injury Pathophysiology

Many intravenous anticancer drugs are designed to target rapidly dividing cancer cells, and some are classified as vesicants with the potential to cause severe local tissue injury if they escape the vasculature. The clinical concern is not simply that leakage occurs, but that these agents remain biologically active within surrounding tissue, where cytotoxic effects may continue even after the infusion has been stopped.¹

Vesicant agents are defined by their ability to cause blistering, ulceration, and tissue necrosis following extravasation. Tissue injury may occur through several mechanisms, including:

  • Direct cytotoxic damage to surrounding tissues
  • DNA binding, resulting in ongoing cellular injury after exposure
  • High osmolarity and non-physiologic pH, contributing to chemical injury and edema
  • Local vasoconstriction, which may impair clearance of the drug and worsen tissue damage

Certain vesicant agents, including some anthracyclines such as doxorubicin, can cause progressive tissue injury that evolves over days or even weeks after the initial event. Clinically, this may lead to ulceration, necrosis, delayed wound healing, or long-term functional impairment, sometimes requiring surgical intervention.³

Because the early stages of infiltration or extravasation may not always be apparent through intermittent visual inspection alone, prompt detection and continuous monitoring of the IV site remain important considerations during vesicant oncology and SACT infusions.

Mechanisms of Infiltration in Clinical Practice

Extravasation may initially occur as low-volume, clinically undetectable drug leakage into surrounding tissue, delaying recognition until signs of tissue injury become apparent.¹

These include:

  • Catheter puncture through the opposing vein wall
  • Increased vein porosity, often associated with repeated venipuncture or cytotoxic exposure
  • Leakage at the insertion site, allowing fluid to track into the interstitial space
  • Catheter dislodgement, particularly with extended dwell times
  • Leakage through the opposing vein wall

Notably, several of these mechanisms may occur while blood return and flushing remain present, creating a false sense of catheter integrity. This challenges the reliability of traditional indicators used to confirm proper IV function.²

In addition to mechanical mechanisms, extravasation may occur due to poorly functioning IV catheters, suboptimal insertion technique, or patient-specific vascular factors such as fragile or previously treated veins. Patients receiving oncology or SACT infusions are particularly vulnerable due to repeated venous access and endothelial damage from prior therapies.³ These factors contribute not only to the likelihood of extravasation, but also to the difficulty in detecting early leakage using conventional clinical indicators.

Clinical Limitations of Conventional Monitoring

Standard monitoring practices in oncology and SACT infusion settings rely on intermittent visual inspection, palpation, and patient-reported symptoms. While these remain essential components of care, they are inherently limited in their ability to detect early infiltration:

  • Initial leakage occurs at the subcutaneous level, often before visible changes develop
  • Assessment intervals introduce gaps in surveillance, during which injury may progress
  • Infusion sites may be obscured by dressings or patient positioning
  • Patients may be unable to perceive or communicate early symptoms

These factors contribute to a recognized clinical gap: the interval between initiation of tissue injury and clinical recognition.

Additional practice considerations further increased risk in oncology and SACT settings:

  • Use of peripheral IV access for vesicant administration, particularly in ambulatory care
  • Fragile or compromised vasculature due to prior treatments
  • Extended catheter dwell times and repeated access attempts

Moreover, IV therapy complications are frequently underrecognized and underreported, and leakage of even small volumes may result in a clinically meaningful injury.²

Clinical presentation of extravasation exists along a spectrum. Early-stage events may present with mild erythema, swelling, or discomfort, whereas more severe cases can progress to ulceration, full-thickness tissue necrosis, and long-term functional impairment. In oncology/SACT care settings, these injuries carry additional implications, including interruption of planned treatment, potential compromise of treatment efficacy, and limitations on future vascular access. The severity of outcome is closely associated with both the type and volume of agent extravasated and the timeliness of intervention.³

Clinical Consequences of Delayed Detection

The severity of extravasation injury is directly influenced by:

  1. The volume of the vesicant extravasated
  2. The duration of exposure prior to intervention

Delayed detection increases the likelihood of:

  • Tissue necrosis and ulceration
  • Neurovascular compromise
  • Compartment syndrome
  • Requirement for surgical management, including debridement or grafting

In oncology and SACT care, these complications may also necessitate interruption or delay of treatment, potentially affecting overall treatment outcomes.³

Continuous Monitoring as an Adjunct to Clinical Practice

Continuous IV site monitoring technologies, such as ivWatch, have been developed to directly address the limitations of intermittent assessment by providing a real-time, objective evaluation of the infusion site for signs of fluid leaking outside the vessel.

The system utilizes optical sensing (visible and near-infrared light) to detect changes in tissue composition associated with fluid accumulation. Unlike traditional assessment methods, ivWatch continuously evaluates the infusion site, taking optical measurements five times per second and enabling near real-time detection of physiologic changes associated with infiltration.⁴

This approach enables:

  • Identification of subclinical infiltration
  • Continuous surveillance independent of visual access
  • Predictive alerts to prompt timely clinical evaluation

Importantly, ivWatch has demonstrated a 99% sensitivity for detecting extravasations of 10 mL or less, supporting reliable identification of clinically significant events at an early stage.⁵ Additionally, the system has demonstrated the potential to notify clinicians with as little as 0.2 mL of infiltrated fluid, highlighting its capability to detect leakage at volumes far below the threshold of clinical visibility.⁶

This capability is particularly relevant in scenarios where conventional indicators, such as blood return or the ability to flush, may remain normal despite active leakage.²

Implications for Oncology and SACT Care Delivery

Within oncology and SACT practice, where vesicant therapies present a narrow safety margin, continuous IV monitoring represents more than an adjunct; it offers a meaningful advancement in early detection and harm prevention.

Specifically, ivWatch:

  • Enhances the ability to detect early physiologic changes preceding visible injury
  • Enables intervention at the earliest stages of infiltration, when injury may still be reversible
  • Supports timely initiation of institutional extravasation management pathways, including antidote administration or saline washouts
  • Provides an additional, technology-enabled safety layer for high-risk peripheral infusions

By narrowing the interval between infiltration onset and clinical response, continuous monitoring aligns with a broader patient safety objective: preventing progression from minor leakage to irreversible tissue injury.

Conclusion

Extravasation during oncology and SACT infusions represents a time-sensitive complication, rather than solely a frequency-based risk. Vesicant agents amplify the clinical consequences of even small-volume infiltration, particularly when detection is delayed.

Given that:

  • Infiltration may occur despite apparently functional IV access
  • Early tissue injury is often clinically silent
  • Outcomes are strongly dependent on time to intervention

The integration of continuous monitoring technologies represents a critical evolution in infusion safety. By enabling earlier detection of subclinical leakage, down to fractions of a milliliter, and maintaining constant surveillance, systems such as ivWatch support a more proactive, evidence-based approach to patient care focused not only on management, but on the prevention of harm through timely awareness.

  1. Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults. UpToDate. https://www.uptodate.com/contents/extravasation-injury-from-cytotoxic-and-other-noncytotoxic-vesicants-in-adults

  2. IVs fail too often. ivWatch. January 16, 2025. https://www.ivwatch.com/2025/01/16/ivs-fail-too-often/

  3. Exploring extravasation in cancer patients. Cancers (Basel). https://www.mdpi.com/2072-6694/16/13/2308

  4. Doellman D, Rineair S. The use of optical detection for continuous monitoring of pediatric IV sites. J Assoc Vasc Access. 2019;24(2):44. https://java.kglmeridian.com/view/journals/jvad/24/2/article-p44.xml

  5. ivWatch, LLC. ivWatch SmartTouch™ Sensor: device validation for non-infiltrated tissues. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04065373

  6. ivWatch SmartTouch™ Sensor: device validation for infiltrated tissues. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04064229